TET2 binds the androgen receptor and loss is associated with prostate cancer.
Nickerson ML, Das S, Im KM, Turan S, Berndt SI, Li H, Lou H, Brodie SA, Billaud JN, Zhang T, Bouk AJ, Butcher D, Wang Z, Sun L, Misner K, Tan W, Esnakula A, Esposito D, Huang WY, Hoover RN, Tucker MA, Keller JR, Boland J, Brown K, Anderson SK, Moore LE, Isaacs WB, Chanock SJ, Yeager M, Dean M, Andresson T.
Nickerson ML, et al. Among authors: esnakula a.
Oncogene. 2017 Apr;36(15):2172-2183. doi: 10.1038/onc.2016.376. Epub 2016 Nov 7.
Oncogene. 2017.
PMID: 27819678
Free PMC article.